B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

382Citations
Citations of this article
315Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Failure of immunization with the HIV-1 envelope to induce broadly neutralizing antibodies against conserved epitopes is a major barrier to producing a preventive HIV-1 vaccine. Broadly neutralizing monoclonal antibodies (BnAbs) from those subjects who do produce them after years of chronic HIV-1 infection have one or more unusual characteristics, including polyreactivity for host antigens, extensive somatic hypermutation and long, variable heavy-chain third complementarity-determining regions, factors that may limit their expression by host immunoregulatory mechanisms. The isolation of BnAbs from HIV-1g-infected subjects and the use of computationally derived clonal lineages as templates provide a new path for HIV-1 vaccine immunogen design. This approach, which should be applicable to many infectious agents, holds promise for the construction of vaccines that can drive B cells along rare but desirable maturation pathways. © 2012 Nature America, All Right Reserved.

Cite

CITATION STYLE

APA

Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012, May). B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nature Biotechnology. https://doi.org/10.1038/nbt.2197

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free